Gastroenterology
Volume 137, Issue 3 , Pages 1180-1181 , September 2009

Reply

References 

  1. Fabrizi F, Dixit V, Martin P. Meta-analysis: terlipressin therapy for the hepatorenal syndrome. Aliment Pharmacol Ther. 2006;24:935–944
  2. Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology. 2008;134:1360–1368
  3. Martín-Llahí M, Pépin MN, Guevara M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology. 2008;134:1352–1359
  4. Salerno F, Gerbes A, Ginès P, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56:1310–1318
  5. Angeli P, Fasolato S, Cavallin M, et al. Terlipressin given as continuous intravenous infusion versus terlipressin given as intravenous boluses in the treatment of type 1 hepatorenal syndrome (HRS) in patients with cirrhosis. J Hepatol. 2009;S73(Suppl 1):175A

 Conflicts of interest The authors disclose no conflicts.

PII: S0016-5085(09)01179-2

doi: 10.1053/j.gastro.2009.07.023

Gastroenterology
Volume 137, Issue 3 , Pages 1180-1181 , September 2009

Article Tools